Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Berg

Showing results (551-560 of 633) with videos related to

Pageof 64
Sort By:
Plos One|January 26, 2012
A common variant of PNPLA3 (p.I148M) is not associated with alcoholic chronic pancreatitisJonas Rosendahl, Anke Tönjes, Dorit Schleinitz, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 18, 2021
Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 LocusAli Bayoumi, Asmaa Elsayed, Shuanglin Han, et al.
Gut|May 20, 2016
Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infectionJanett Fischer, Alexander N R Weber, Stephan Böhm, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 10, 2019
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 InfectionsJulia Dietz, Ulrich Spengler, Beat Müllhaupt, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 18, 2016
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in PatientsSarah Berhane, Hidenori Toyoda, Toshifumi Tada, et al.
Journal of Viral Hepatitis|May 13, 2020
Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infectionJulia Dietz, Olga V Kalinina, Johannes Vermehren, et al.
The American Journal of Gastroenterology|June 14, 2018
Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related CirrhosisFelix Stickel, Stephan Buch, Hans Dieter Nischalke, et al.
Journal of Hepatology|June 20, 2020
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
Journal of Hepatology|August 8, 2021
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)Cornelius Engelmann, Adam Herber, Annegret Franke, et al.
Alimentary Pharmacology & Therapeutics|February 10, 2021
Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosisStephan Buch, Aneesh Sharma, Eleanor Ryan, et al.
Pageof 64

Showing results (551-560 of 633) with videos related to

Sort By:
Pageof 64
Plos One|January 26, 2012
A common variant of PNPLA3 (p.I148M) is not associated with alcoholic chronic pancreatitisJonas Rosendahl, Anke Tönjes, Dorit Schleinitz, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 18, 2021
Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 LocusAli Bayoumi, Asmaa Elsayed, Shuanglin Han, et al.
Gut|May 20, 2016
Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infectionJanett Fischer, Alexander N R Weber, Stephan Böhm, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 10, 2019
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 InfectionsJulia Dietz, Ulrich Spengler, Beat Müllhaupt, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 18, 2016
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in PatientsSarah Berhane, Hidenori Toyoda, Toshifumi Tada, et al.
Journal of Viral Hepatitis|May 13, 2020
Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infectionJulia Dietz, Olga V Kalinina, Johannes Vermehren, et al.
The American Journal of Gastroenterology|June 14, 2018
Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related CirrhosisFelix Stickel, Stephan Buch, Hans Dieter Nischalke, et al.
Journal of Hepatology|June 20, 2020
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, George N Dalekos, Ramazan Idilman, et al.
Journal of Hepatology|August 8, 2021
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)Cornelius Engelmann, Adam Herber, Annegret Franke, et al.
Alimentary Pharmacology & Therapeutics|February 10, 2021
Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosisStephan Buch, Aneesh Sharma, Eleanor Ryan, et al.
Pageof 64